Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067048 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL5388756 | 0.78 | POLB (0.67) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL7054779 | 0.76 | CYP1A2 (0.61) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL2673753 | 0.76 | RECQL (0.71) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL19665240 | 0.73 | PIN1 (0.62) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL4067341 | 0.72 | ALDH1A1 (0.56) | CYP1A2CYP2C19SMN1; SMN2POLBMAPK1 | |
| SCHEMBL9820174 | 0.72 | ALDH1A1 (0.57) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL1145344 | 0.72 | SMN1; SMN2 (0.56) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL23484280 | 0.71 | SMN1; SMN2 (0.58) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR | |
| SCHEMBL31456931 | 0.70 | CYP1A2 (0.54) | CYP1A2CYP2C19SMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601736-B2 | Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics | SK CHEMICALS CO., LTD. (KR) | 2009-10-13 | — | — | US | disclosed |
| EP-1706412-A4 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS CO LTD (KR) | 2009-03-18 | — | — | EP | disclosed |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | SK CHEMICALS CO., LTD. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1706412-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK Chemicals, Co., Ltd. (KR) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063768-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS, CO., LTD. (KR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | IL5, IL1B, P2RY4 | CYP1A2 161/4885CYP2C19 155/4885SMN1; SMN2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.